Literature DB >> 3600187

Decreased muscarinic receptor binding in cerebral cortex and hippocampus in Alzheimer's disease.

K J Reinikainen, P J Riekkinen, T Halonen, M Laakso.   

Abstract

Muscarinic (cholinergic) receptor binding sites (MRB) were studied by determining the 3H-QNB binding in four cortical areas and hippocampus of 20 histologically confirmed Alzheimer patients and comparing these with corresponding controls. Alzheimer patients dying at younger age (less than or equal to 80) with profound decrease in choline-acetyltransferase activity (by 61-85%) and without any, possibly MRB modifying, drug treatment showed 30% decrease in MRB in the frontal cortex (p less than 0.05), 28% in the temporal cortex (p less than 0.05) and 37% in the hippocampus (p less than 0.01). These findings further suggest that muscarinic receptors are affected in Alzheimer's disease, at least in advanced state of the disease.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3600187     DOI: 10.1016/0024-3205(87)90221-9

Source DB:  PubMed          Journal:  Life Sci        ISSN: 0024-3205            Impact factor:   5.037


  8 in total

1.  In vivo metabolic studies of the trans-(R,R) isomer of radioiodinated IQNP: a new ligand with high affinity for the M1 muscarinic-cholinergic receptor.

Authors:  D W McPherson; C R Lambert; F F Knapp
Journal:  Eur J Nucl Med       Date:  1994-12

2.  Cholinesterase inhibitors improve both memory and complex learning in aged beagle dogs.

Authors:  Joseph A Araujo; Nigel H Greig; Donald K Ingram; Johan Sandin; Christina de Rivera; Norton W Milgram
Journal:  J Alzheimers Dis       Date:  2011       Impact factor: 4.472

3.  Muscarinic receptor occupancy and cognitive impairment: a PET study with [11C](+)3-MPB and scopolamine in conscious monkeys.

Authors:  Shigeyuki Yamamoto; Shingo Nishiyama; Masahiro Kawamata; Hiroyuki Ohba; Tomoyasu Wakuda; Nori Takei; Hideo Tsukada; Edward F Domino
Journal:  Neuropsychopharmacology       Date:  2011-03-23       Impact factor: 7.853

4.  Increased CSF HVA response to arecoline challenge in Alzheimer's disease.

Authors:  N Pomara; M Stanley; P A LeWitt; M Galloway; R Singh; D Deptula
Journal:  J Neural Transm Gen Sect       Date:  1992

5.  Differential cholinergic regulation in Alzheimer's patients compared to controls following chronic blockade with scopolamine: a SPECT study.

Authors:  T Sunderland; G Esposito; S E Molchan; R Coppola; D W Jones; J Gorey; J T Little; M Bahro; D R Weinberger
Journal:  Psychopharmacology (Berl)       Date:  1995-09       Impact factor: 4.530

6.  Higher levels of different muscarinic receptors in the cortex and hippocampus from subjects with Alzheimer's disease.

Authors:  Elizabeth Scarr; Catriona McLean; Brian Dean
Journal:  J Neural Transm (Vienna)       Date:  2016-09-29       Impact factor: 3.575

7.  Reduction of [11C](+)3-MPB binding in brain of chronic fatigue syndrome with serum autoantibody against muscarinic cholinergic receptor.

Authors:  Shigeyuki Yamamoto; Yasuomi Ouchi; Daisaku Nakatsuka; Tsuyoshi Tahara; Kei Mizuno; Seiki Tajima; Hirotaka Onoe; Etsuji Yoshikawa; Hideo Tsukada; Masao Iwase; Kouzi Yamaguti; Hirohiko Kuratsune; Yasuyoshi Watanabe
Journal:  PLoS One       Date:  2012-12-11       Impact factor: 3.240

8.  Novel Variance-Component TWAS method for studying complex human diseases with applications to Alzheimer's dementia.

Authors:  Shizhen Tang; Aron S Buchman; Philip L De Jager; David A Bennett; Michael P Epstein; Jingjing Yang
Journal:  PLoS Genet       Date:  2021-04-02       Impact factor: 5.917

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.